The manufacturer reached a distribution agreement with the online service and withdrew its legal action. Stock in the telehealth firm jumped sharply on the news. Commenters noted that consumers end up paying more while companies benefit, and speculated that generics or telehealth workarounds will eventually lower prices.
What this discussion establishesWhether consumers will stay disadvantaged or telehealth will keep offering lower-cost options once generics arrive
Nothing here is advice.
The manufacturer reached an agreement to distribute its major weight-loss and diabetes medications through the telehealth platform, ending the lawsuit that started the previous month.
The telehealth company's shares rose more than forty percent in today's trading.
They offered a cheaper oral version, got sued, made a deal, and prices went back up. Everyone wins except the people paying, unless you bought shares when they were low.
It's such a relief knowing those giant businesses will pull through just fine.
Big pharma strikes again. When the active ingredient finally goes generic the monthly cost will probably drop below a hundred dollars.
I see telehealth outfits using the same model stepping in to fill demand. You answer questions, a doctor reviews it, and you receive the medication, or at least whichever versions get reclassified. The rest of the unregulated market stays wide open.
Not a hint of subtlety showed up in the way they pushed their oral imitation.
My doctor will be delighted since he thinks I am getting the compounded version through that service.
Who saw this coming? Sue them to shut down the cheaper option, then realize they reached more customers than your own efforts and partner up so both sides can profit off the public.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.